US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tvardi Therapeutics Inc

3.72

+0.17004.79%

Post-market: 3.65-0.0700-1.88%16:43 EST

Volume:100.75K

Turnover:368.87K

Market Cap:34.90M

PE:-0.47

High:3.75

Open:3.56

Low:3.50

Close:3.55

52wk High:43.65

52wk Low:3.50

Shares:9.38M

Float Shares:7.78M

Volume Ratio:1.32

T/O Rate:1.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-7.8700

EPS(LYR):-4.5947

ROE:-135.64%

ROA:-72.68%

PB:1.25

PE(LYR):-0.81

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases

BRIEF-Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo

Tvardi Therapeutics Inc - Topline Healthy Volunteer Data From Phase 1 Study of Next-Generation Stat3 Inhibitor, Tti-109, on Track for H1 2026

THOMSON REUTERS

Tvardi Therapeutics Reports Phase 2 Data Showing TTI-101 Reduces Fibrosis in IPF Patients

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TVRD"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","market":"US","secType":"STK","nameCN":"Tvardi Therapeutics Inc","latestPrice":3.72,"timestamp":1770411600000,"preClose":3.55,"halted":0,"volume":100750,"hourTrading":{"tag":"盘后","latestPrice":3.65,"preClose":3.72,"latestTime":"16:43 EST","volume":2379,"amount":8790.38,"timestamp":1770414237475,"change":-0.07,"changeRate":-0.018817,"amplitude":0.018817},"delay":0,"changeRate":0.04788732394366208,"floatShares":7778729,"shares":9381344,"eps":-7.87,"marketStatus":"Closed","change":0.17,"latestTime":"02-06 16:00:00 EST","open":3.56,"high":3.75,"low":3.5,"amount":368873.25475,"amplitude":0.070423,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.87,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":5,"adr":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":3.55,"preHourTrading":{"tag":"盘前","latestPrice":3.56,"preClose":3.55,"latestTime":"09:10 EST","volume":42,"amount":149.52,"timestamp":1770387033287,"change":0.01,"changeRate":0.002817,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.65,"preClose":3.72,"latestTime":"16:43 EST","volume":2379,"amount":8790.38,"timestamp":1770414237475,"change":-0.07,"changeRate":-0.018817,"amplitude":0.018817},"volumeRatio":1.321395,"impliedVol":1.9529,"impliedVolPercentile":0.4904},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVRD\",,,,,undefined,":{"symbol":"TVRD","floatShares":7778729,"roa":"-72.68%","roe":"-135.64%","lyrEps":-4.594733,"volumeRatio":1.321395,"shares":9381344,"dividePrice":0,"high":3.75,"amplitude":0.070423,"preClose":3.55,"low":3.5,"week52Low":3.5,"pbRate":"1.25","week52High":43.65,"institutionHeld":0,"latestPrice":3.72,"eps":-7.87,"divideRate":0,"volume":100750,"delay":0,"ttmEps":-7.87,"open":3.56,"prevYearClose":4.3,"prevWeekClose":3.97,"prevMonthClose":3.97,"prevQuarterClose":4.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-13","symbol":"TVRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.59},{"market":"US","date":"2025-08-14","symbol":"TVRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2025-05-13","symbol":"TVRD","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":-3.22},{"market":"US","date":"2025-04-16","symbol":"TVRD","defaultRemindTime":1744810200000,"type":"split","dateTimestamp":1744776000000,"forFactor":3,"toFactor":1,"ratio":3},{"market":"US","date":"2025-03-11","symbol":"TVRD","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.25,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.25,"analysts":8,"updateTime":1770267600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TVRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TVRD","date":"2026-02-05","current":-0.472681,"percent":0.984962,"low":-17.054928,"twenty":-12.039637,"median":-1.906508,"eighty":-1.626425,"high":-1.48778,"avg":-5.79843,"sd":5.319476,"marketCap":36211987},"quantilePoints":[{"date":"2025-08-01","current":-6.984237,"twenty":-7.018674,"median":-6.984237,"eighty":-6.867475,"marketCap":242869870},{"date":"2025-08-08","current":-6.220168,"twenty":-7.05634,"median":-6.986928,"eighty":-6.651705,"marketCap":216300131},{"date":"2025-08-15","current":-6.400424,"twenty":-7.003609,"median":-6.690985,"eighty":-6.397734,"marketCap":222568344},{"date":"2025-08-22","current":-10.573024,"twenty":-9.576632,"median":-6.986928,"eighty":-6.42948,"marketCap":249861702},{"date":"2025-08-29","current":-12.013447,"twenty":-10.759129,"median":-7.048807,"eighty":-6.480866,"marketCap":283901784},{"date":"2025-09-05","current":-12.078921,"twenty":-11.588463,"median":-7.134899,"eighty":-6.493511,"marketCap":285449060},{"date":"2025-09-12","current":-14.047103,"twenty":-11.928926,"median":-9.803211,"eighty":-6.612426,"marketCap":331961128},{"date":"2025-09-19","current":-15.372451,"twenty":-12.457478,"median":-10.666275,"eighty":-6.823352,"marketCap":363281754},{"date":"2025-09-26","current":-14.606606,"twenty":-13.432046,"median":-11.499578,"eighty":-6.955181,"marketCap":345183308},{"date":"2025-10-03","current":-14.82882,"twenty":-14.620891,"median":-11.737664,"eighty":-6.987466,"marketCap":350434671},{"date":"2025-10-10","current":-17.054928,"twenty":-14.850248,"median":-11.943013,"eighty":-6.991233,"marketCap":403042070},{"date":"2025-10-17","current":-2.571334,"twenty":-14.850248,"median":-11.769409,"eighty":-6.823352,"marketCap":60765765},{"date":"2025-10-24","current":-2.047544,"twenty":-14.833582,"median":-11.58886,"eighty":-6.422216,"marketCap":48387554},{"date":"2025-10-31","current":-1.849138,"twenty":-14.74787,"median":-11.130543,"eighty":-4.843171,"marketCap":43698837},{"date":"2025-11-07","current":-1.563435,"twenty":-14.662953,"median":-10.195062,"eighty":-2.595143,"marketCap":36947086},{"date":"2025-11-14","current":-1.631573,"twenty":-14.620891,"median":-9.523459,"eighty":-2.06421,"marketCap":38557323},{"date":"2025-11-21","current":-1.515552,"twenty":-14.489944,"median":-7.06764,"eighty":-1.887232,"marketCap":35836734},{"date":"2025-11-28","current":-1.634574,"twenty":-14.266143,"median":-6.990963,"eighty":-1.811838,"marketCap":38651137},{"date":"2025-12-05","current":-1.658378,"twenty":-13.805842,"median":-6.911597,"eighty":-1.667399,"marketCap":39214017},{"date":"2025-12-12","current":-1.781368,"twenty":-13.436014,"median":-6.493242,"eighty":-1.662637,"marketCap":42122234},{"date":"2025-12-19","current":-1.543324,"twenty":-13.412999,"median":-6.400424,"eighty":-1.660082,"marketCap":36493428},{"date":"2025-12-26","current":-1.5949,"twenty":-13.32332,"median":-6.349307,"eighty":-1.639335,"marketCap":37713002},{"date":"2026-01-02","current":-1.705987,"twenty":-13.031267,"median":-2.777676,"eighty":-1.642509,"marketCap":40339779},{"date":"2026-01-09","current":-1.678216,"twenty":-12.62652,"median":-2.62292,"eighty":-1.634574,"marketCap":39683085},{"date":"2026-01-16","current":-1.789303,"twenty":-12.344784,"median":-2.448323,"eighty":-1.634574,"marketCap":42309861},{"date":"2026-01-23","current":-1.91626,"twenty":-12.181298,"median":-2.07532,"eighty":-1.634574,"marketCap":45311891},{"date":"2026-01-30","current":-1.547291,"twenty":-12.091222,"median":-1.95231,"eighty":-1.634574,"marketCap":36587241},{"date":"2026-02-05","current":-1.531421,"twenty":-12.039637,"median":-1.906508,"eighty":-1.626425,"marketCap":36211987}],"updateTime":1770432863342},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVRD\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603934475","title":"Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2603934475","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603934475?lang=en_us&edition=fundamental","pubTime":"2026-01-16 08:04","pubTimestamp":1768521893,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. has released a new corporate presentation highlighting progress in its development of therapies targeting STAT3 biology for fibrosis-driven diseases and cancers. The company reports demonstrated target engagement and disease modification across animal models, as well as observed reductions in fibrosis and inflammation markers in clinical studies. Tvardi’s lead program, TTI-101, is being evaluated for idiopathic pulmonary fibrosis  and hepatocellular carcinoma , with additional data from ongoing trials expected in the near term. The presentation also notes the advancement of TTI-109, a prodrug designed to enhance delivery and tolerability of STAT3 inhibition, currently in a Phase 1 trial with healthy volunteers. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLbkMQfs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVRD","BK4007"],"gpt_icon":0},{"id":"2601362494","title":"BRIEF-Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362494","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362494?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:35","pubTimestamp":1767879304,"startTime":"0","endTime":"0","summary":"BRIEF-Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% PlaceboJan 8 (Reuters) - Tvardi Therapeutics Inc TVRD.O:TVARDI THERAPEUTICS INC - TTI-101 SHOWS 9.4% FIBROSIS SCORE DEC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2601364234","title":"Tvardi Therapeutics Inc - Topline Healthy Volunteer Data From Phase 1 Study of Next-Generation Stat3 Inhibitor, Tti-109, on Track for H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364234?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:11","pubTimestamp":1767877894,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90F9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TVRD"],"gpt_icon":0},{"id":"2601364566","title":"Tvardi Therapeutics Reports Phase 2 Data Showing TTI-101 Reduces Fibrosis in IPF Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364566","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364566?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:02","pubTimestamp":1767877372,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics Inc. has announced further updates from its Phase 2 REVERT IPF clinical trial evaluating TTI-101, an oral STAT3 inhibitor, in patients with idiopathic pulmonary fibrosis . Data from the study, which was previously announced as not meeting its primary endpoints in October 2025, include additional analyses on a subset of 40 patients who completed 12 weeks of treatment. The results show a 9.4% decrease from baseline in fibrosis score for patients treated with TTI-101, compared to a 2.4% decrease in the placebo group. Additionally, 63% of patients in the TTI-101 group experienced an increase in forced vital capacity  at 12 weeks, versus 46% in the placebo group. The company has also stated that topline healthy volunteer data from a Phase 1 study of its next-generation STAT3 inhibitor, TTI-109, is expected in the first half of 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL8W0KM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","BK4007","IE00BGHQF748.EUR","NDAQ","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","TVRD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","BK4588","LU2210149790.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TVRD\",params:#limit:6,delay:false,,,undefined,":[]}}